share_log

D: Filing D

D: Filing D

D：发行公告
美股sec公告 ·  04/25 16:08
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
在以色列注册的生物技术公司NeuroSense Therapeutics Ltd. 已成功完成证券的豁免发行，根据向美国证券交易委员会（SEC）提交的新Form D通知中所述，共筹集了4470,000美元。此次发行包括期权、认股权证或其他收购证券的权利，是根据《证券法》第506（b）条进行的。首次出售日期为2024年4月15日，该公司打算此次发行持续一年以上。NeuroSense Therapeutics拒绝透露其收入范围或总净资产价值。该公司还证实，此次发行与业务合并交易无关。已支付配售代理费，其中包括现金费和公司的普通股。本次发行的投资者总数为一人，不建议将此次发行的收益用于向执行官、董事或发起人付款。NeuroSense Therapeutics 首席执行官 Alon Ben-Noon 于 2024 年 4 月 25 日签署了该文件。
在以色列注册的生物技术公司NeuroSense Therapeutics Ltd. 已成功完成证券的豁免发行，根据向美国证券交易委员会（SEC）提交的新Form D通知中所述，共筹集了4470,000美元。此次发行包括期权、认股权证或其他收购证券的权利，是根据《证券法》第506（b）条进行的。首次出售日期为2024年4月15日，该公司打算此次发行持续一年以上。NeuroSense Therapeutics拒绝透露其收入范围或总净资产价值。该公司还证实，此次发行与业务合并交易无关。已支付配售代理费，其中包括现金费和公司的普通股。本次发行的投资者总数为一人，不建议将此次发行的收益用于向执行官、董事或发起人付款。NeuroSense Therapeutics 首席执行官 Alon Ben-Noon 于 2024 年 4 月 25 日签署了该文件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息